Rytelo® (imetelstat)
for Myelodysplastic Syndromes
Rytelo (imetelstat) is an injectable telomerase inhibitor used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. It offers the potential for over 24 weeks of freedom from red blood cell transfusions or anemia symptoms. Rytelo works by inhibiting telomerase activity, reducing telomere length and malignant stem and progenitor cells, leading to cell death and helping manage MDS symptoms.
